Biofrontera Inc. (BFRI) Income Statement
BFRI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBFRI revenue and net income
Where BFRI's revenue goes
2025Each bar shows an amount and its share of revenue. BFRI kept −25.3% of revenue as net income.
BFRI profit margins
BFRI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +11.8% | +13.3% | +17.2% | — |
| Gross profit | +75.5% | +34.5% | +27.4% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BFRI quarterly EPS vs estimates
Biofrontera beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.33).
BFRI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M | $18.8M | $26.2M |
| Cost of revenue | $8.9M | $18.6M | $17.4M | $15.2M | $12.7M | $9.1M | $12.4M |
| Gross profit | $32.8M | $18.7M | $16.6M | $13.5M | $11.4M | $9.8M | $13.8M |
| Research & development | $3.7M | $2.1M | $77,000 | $0 | — | — | — |
| Sales, general & admin | $38.4M | $33.8M | $39.1M | $35.9M | $37.2M | $18.1M | $28.7M |
| Total operating expenses | $42.0M | $35.9M | $39.3M | $32.1M | $36.6M | $19.4M | $28.7M |
| Operating income | −$9.1M | −$17.2M | −$22.7M | −$18.6M | −$25.2M | −$9.6M | −$14.9M |
| Interest income | — | $71,000 | $168,000 | $175,000 | $16,000 | $28,000 | $25,000 |
| Interest expense | $452,000 | $2.1M | $600,000 | $370,000 | $360,000 | $2.9M | $2.2M |
| Income before taxes | −$10.5M | −$17.7M | −$20.1M | −$608,000 | −$37.7M | −$10.9M | −$10.9M |
| Income taxes | $25,000 | $22,000 | $14,000 | $32,000 | $56,000 | $64,000 | $33,000 |
| Net income | −$10.5M | −$17.8M | −$20.1M | −$640,000 | −$37.7M | −$11.0M | −$11.0M |
| EBITDA | −$9.2M | −$14.4M | −$18.5M | $934,000 | −$36.8M | −$7.5M | −$8.1M |
| EPS (diluted) | −$1.11 | −$5.00 | −$13.13 | −$20.12 | −$10.32 | −$27.47 | — |
| Gross margin | 78.7% | 50.1% | 48.8% | 47.0% | 47.1% | 51.9% | 52.6% |
| Operating margin | −21.9% | −46.1% | −66.6% | −64.8% | −104.6% | −51.0% | −57.0% |
| Net margin | −25.3% | −47.6% | −59.1% | −2.2% | −156.5% | −58.3% | −41.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M | $10.1M | $17.1M | $7.0M | $9.0M | $8.6M | $12.6M | $9.0M | $7.8M | $7.9M | $10.6M | $8.9M |
| Cost of revenue | $2.4M | $1.8M | $871,000 | $2.1M | $2.7M | $3.3M | $5.3M | $4.9M | $4.3M | $3.9M | $5.4M | $4.6M |
| Gross profit | $9.6M | $8.3M | $16.2M | $4.9M | $6.4M | $5.3M | $7.3M | $4.1M | $3.5M | $4.0M | $5.2M | $4.3M |
| Research & development | $448,000 | $900,000 | $787,000 | $837,000 | $848,000 | $1.2M | $783,000 | $669,000 | $621,000 | $17,000 | $33,000 | $33,000 |
| Sales, general & admin | $9.7M | $11.0M | $8.7M | $10.4M | $10.6M | $8.7M | $8.2M | $8.4M | $7.9M | $9.2M | $9.1M | $8.8M |
| Total operating expenses | $10.1M | $12.6M | $9.5M | $11.2M | $11.4M | $9.8M | $9.0M | $9.1M | $8.6M | $9.4M | $9.1M | $8.9M |
| Operating income | −$524,000 | −$4.3M | $6.8M | −$6.3M | −$5.1M | −$4.5M | −$1.7M | −$5.0M | −$5.1M | −$5.5M | −$3.9M | −$4.6M |
| Interest income | — | — | — | — | — | $14,000 | $15,000 | $17,000 | $24,000 | $14,000 | $21,000 | $13,000 |
| Interest expense | $126,000 | $125,000 | $120,000 | $111,000 | $115,000 | $120,000 | $55,000 | $9,000 | $620,000 | $1.4M | $233,000 | $155,000 |
| Income before taxes | −$581,000 | −$4.8M | $5.6M | −$6.6M | −$5.3M | −$4.2M | −$1.4M | −$5.7M | −$237,000 | −$10.4M | $3.5M | −$6.3M |
| Income taxes | $23,000 | — | −$1,000 | $6,000 | $21,000 | −$1,000 | −$3,000 | $3,000 | $20,000 | $1,000 | −$6,000 | $1,000 |
| Net income | −$604,000 | −$4.8M | $5.6M | −$6.6M | −$5.3M | −$4.2M | −$1.4M | −$5.7M | −$257,000 | −$10.4M | $3.5M | −$6.3M |
| EBITDA | −$397,000 | −$4.7M | $6.0M | −$6.3M | −$5.0M | −$3.9M | −$1.1M | −$5.3M | $692,000 | −$8.7M | $4.0M | −$5.9M |
| EPS (diluted) | −$0.05 | −$0.41 | $0.50 | −$0.57 | −$0.57 | −$0.47 | −$0.23 | −$0.81 | −$1.08 | −$2.88 | −$0.68 | −$3.16 |
| Gross margin | 79.9% | 81.8% | 94.9% | 70.4% | 70.5% | 61.6% | 58.0% | 45.9% | 44.6% | 50.1% | 49.3% | 48.4% |
| Operating margin | −4.4% | −42.8% | 39.5% | −89.8% | −56.2% | −52.9% | −13.6% | −55.0% | −64.7% | −69.2% | −36.5% | −51.9% |
| Net margin | −5.0% | −47.1% | 33.0% | −95.1% | −59.0% | −48.9% | −11.1% | −62.9% | −3.3% | −132.1% | 33.3% | −71.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BFRI's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BFRI financial results
In fiscal year 2025 (ended December 31, 2025), Biofrontera reported revenue of $41.7 million, up 11.8% from the year before. It had a net loss of $10.5 million, a net profit margin of −25.3%. Diluted earnings per share came to −$1.11. Over five years revenue grew at an average rate of 17.2% a year.
See the BFRI stock overview for the latest quote and news, or the BFRI chart for price history and technical indicators.
BFRI income statement FAQ
What is Biofrontera's annual revenue?
Biofrontera reported total revenue of $41.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 11.8% from $37.3 million the previous year.
Is Biofrontera profitable?
No. Biofrontera reported a net loss of $10.5 million in fiscal 2025, a net profit margin of −25.3%; its operating margin was −21.9%.
What is Biofrontera's gross margin?
Biofrontera's gross margin was 78.7% in fiscal 2025: for every $100 of revenue, Biofrontera kept $79 after the direct cost of its products and services.
How much does Biofrontera spend on research and development?
Biofrontera spent $3.7 million on research and development in fiscal 2025, 8.9% of revenue.
How fast is Biofrontera growing?
Revenue grew 17.2% a year on average over the last five fiscal years, from $18.8 million to $41.7 million.
What are Biofrontera's earnings per share?
Biofrontera earned $-1.11 per diluted share in fiscal 2025, compared with $-5.00 a year earlier.
When will Biofrontera report its next earnings?
Biofrontera is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Biofrontera's fiscal year end?
Biofrontera's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.